Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"The Pitch" is an 'Orthopedics This Week' publication with 122 subscribers
<<<<<<< So the Pitch didn't generate any retail buying momentum to speak of >>>>>>> It was not targeting retail buyers
It is an industry specific, continuing education format that is only going to attract those in Orthopedics or those following this branch of medicine.
Very little chance that a viewer of 'The Pitch' will see BIEL's episode and buy a million shares. However, It will be seen by some Orthopedic Surgeons and some positives could flow from that. It could also be seen by a Venture Capital player who likes the growth prospects of Orthopedics.
"RRY Publications & OTW Broadcasting
Best Continuing Education in Orthopedics"
If there had been even 1 year, in the 12 years that I have been following BIEL, where that claim was not made I might give it some weight. Unfortunately that is not the case.
<<<<<<<<<<<<<< done, finished, end of story >>>>>>>>>>>>>>>>
LOL, The Pitch was broadcast 4 weeks ago
How does anyone on this Board know what investor interest it has had to date or what investor interest it will have in the future???
Investor interest does not translate into immediate SP appreciation.
What is so hard to understand about a 'No Risk' promotion???
BIEL spent Zero $$$$ on The Pitch.
'The Pitch' is aimed at attracting Investors not retail sales
BIEL's appearance on 'The Pitch' did not involve any cost to BIEL.
Thanks Hawk, Glad to see Dr. Staelin answering questions
He is now well into his eighties but no signs that his age has affected his cognitive function at all. All his knowledge from years with BIEL was right there when the questions were asked.
Also interesting to learn that RecoveryRx is being sold to Doctors at $50 a copy. That provides an excellent Margin considering ActiPatch wholesales in the $12-15 range depending on quantity.
The Pitch needs to work on their audio quality. Very distracting to hear static drowning out voices over and over.
U.S. surpasses record 100,000 overdose deaths in 2021
More Americans died of drug overdoses in 2021 than any previous year, a grim milestone in an epidemic that has now claimed 1 million lives in the 21st century, according to federal data released Wednesday.
More than 80,000 people died using opioids, including prescription pain pills and fentanyl
Since the start of the 21st century, an overdose epidemic led by prescription pain pills and followed by waves of heroin, fentanyl and meth has killed more than 1 million people, or roughly the population of San Jose, according to the provisional data.
ActiPatch, No addiction, No side effects, just pain relief.
https://www.msn.com/en-us/news/us/u-s-surpasses-record-100-000-overdose-deaths-in-2021/ar-AAX9nBf?ocid=msedgdhp&pc=U531&cvid=f6d763cd435645dabec810e9799a4db1
Excuse - a reason or explanation put forward to defend or justify a fault or offense
Fact - a thing that is known or proved to be true
<<<<<<<< So the chip shortage will no longer be an excuse for poor revenues >>>>>>>>
So the 'Chip Shortage', documented in hundreds of news articles, was just an 'Excuse' by Ford for poor performance in 2021???
Ford sold 1.9 million vehicles in the U.S. in 2021, down by 6.8% as it managed through a global shortage of semiconductor chips. The parts problem forced Ford and other automakers to sporadically shutter plants and depleted vehicle inventories.Feb 4, 2022
Ford’s sales fell 27 percent in the third quarter because of chip shortages.
The automaker was forced to idle many of its plants for parts of August and September because it did not have enough electronic parts that use computer chips. NYT Published Oct. 4, 2021
So the 'Chip Shortage', documented in hundreds of news articles, was just an 'Excuse' by Sony for poor performance in 2021???
Sony cuts PS5 production by a MILLION units due to chip shortages and shipping issues Sony is reportedly cutting production of its PlayStation 5 gaming console due to a global chip shortage and shipping issues plaguing the technology industry.
So the 'Chip Shortage', documented in hundreds of news articles, was just an 'Excuse' by Panasonic for poor performance in 2021???
Panasonic to halt production of solar panel part due to chip shortage
July 14, 2021 - Japan-based Panasonic Corp. will soon suspend the production of power conditioners - used in residential rooftop solar systems – due to the global shortage of semiconductors, Nikkei reported. Panasonic is expected to suffer a production loss of up to 30% due to the semiconductor shortage
Should install Wheels on that Goalpost so it is easier to move
Consumers are responding favorably to KT's recent price drop to $24.
Pricing on a novel product like Pulsed Shortwave Therapy is an unknown. Better to start high and adjust lower. KT just dropped the price on both Amazon and Walmart and Sales are spiking!!
Go KT Wave !!!
Go BIEL !!!
Nice little 7 Million Share Buy at 2:27 !!
7,142,857 shares cleans out the 7 Ask.
Thanks Hawk, Nice to see the Upscale Clamshell Box (same as the KT box) hit the market for ActiPatch
Ram has inventory in stock.
One Globe Bio has the 'Clamshell box' ActiPatch along with the Smart Insole, Smart Insole Refill, and ActiPatch Knee all in stock.
Italy is leading the way with this new packaging that adds value to ActiPatch.
https://shop.oneglobebio.com/it/prodotti/32-actipatch-kit-per-dolori-acuti-senza-farmaci.html
https://www.elettromedicali.it/categoria-terapia-e-riabilitazione/magnetoterapia/magnetoterapie/
https://www.elettromedicali.it/chi-siamo/#/dfclassic/query=actipatch&query_name=match_and
Pretty simple if one acknowledges the Facts and the Timeline detailed previously, reread post 209414 for details
The Timeline is not being acknowledge.
BIEL used up its Raw Materials in 2021 filling OEM orders, the majority going to KT. Fact, Raw materials at EOY 2020 - $136k, Raw Materials at EOY 2021 - Zero .
More Demand in 2021 than BIEL could meet due to Chip shortage limited 2021 Sales.
Fact, As of 2/28/2022 BIEL found enough Raw Materials to send over $200k in devices to fill 3 International customer orders per the 2/28/2022 Company Update.
There was a Chip shortage affecting BIEL's production ability in 2021. BIEL has found a source for Chips in 2022 as shown by the Q1 2022 $200k International shipment and the scheduled Q2 Launch of SAI Brands 'Powered BY ActiPatch' Products.
Companies run into problems all the time. BIEL found a solution to the global Chip shortage problem that interrupted their Chip supply in 2021 and is producing devices and filling orders in 2022.
So much Disinformation, where to start......
<<<<<<<< BIEL's sales were that bad in 2021 >>>>>>>>>>
BIEL's Sales of $1.6 million for 2021 were the 4th highest in BIEL's 20 year history only eclipsed during the 3 years that BIEL was selling on UK retail shelves.
But Sales are only part of the equation. How much it cost to generate those Sales is also very important.
2021 - Sales $1.6 million - Loss from Operations $157k
2017- Sales $1.76 million - Loss from Operations $1.36 million
2016 - Sales $2.08 million - Loss from Operations $1.4 million
2015 - Sales $2.33 million - Loss from Operations $1.78 million
These numbers tell the story. 2021 was the closest BIEL has ever come to having a Profitable Year, by a wide margin. That is because the OEM business saves a lot of money vs the Retail business plan. OEM is BIEL's Path to Profitability.
The Chip issue slowed down BIEL's move into the OEM business but it is far from a fatal problem. SAI is scheduled to Launch this Quarter with 9 'Powered By ActiPatch' products which will require tens of thousands of devices from BIEL.
Chemist 4U, who was out of stock on Actipatch for 6 months, now has 4 ActiPatch products in stock.
All businesses face problems every day. The shortage of Chips was not caused by BIEL, it is a global issue. BIEL is working through this problem and producing devices for its customers.
KT's Initial order for the Wave was December 2020
<<<<<<<< When will KT Tape restock? Are they going to buy another $900k worth of product when they couldn't sell the initial stock in 15 months? >>>>>>>>
12/21/2020 - 3,770 cartons, 18 pallets, 9,554 lbs , BOL#ZIMUHKG83124564
This initial order was followed 4 months later by a Reorder that was 14% larger than the initial order,
4/25/2021 - 4,332 cartons, 20 pallets, 11,384 lbs, BOL#00LU2661696645
The second Reorder followed 2 months later.
6/28/2021 - 2,848 cartons, 14 pallets, 7,790 lbs, BOL#00LU2665591762
This is all factual information from US Customs records but it does not account for all of BIEL's Sales.
Q3 2021 had $414k in Sales but there are no US Customs records showing BIEL shipments arriving during Q3 . So our US Customs information confirms 3 shipments to KT but does not account for any of BIEL's Revenue in Q3 2021.
Possible reasons include:
BIEL's Chinese manufacturer, CICD, shipped all orders direct to International customers
KT's manufacturer for its Tape products is also located in China, with the Supply Chain disruption causing shipping price increases 3x-10x normal KT may be integrating Wave product with Tape product to reduce shipping costs
LOL, now $3 million is "They haven't spent much"
KT is a Privately held company so their annual revenue is a guessing game.
$3 million is pocket change to a billion $$$$ a year company but KT is definitely not a billion dollar company. The entire Kinesiology Tape Market is estimated to be $350 million annually.
So, KT would not be investing $1, $2, or $3 million in a new product unless they felt it had high probability of success .
Some do not want to admit it, because they feel it reflects poorly on BIEL, but I continue to believe that BIEL has not been able to produce enough devices to meet the demand. This is due to the Covid induced Chip shortage,
What OEM Partner is going to spend hundreds of thousands or millions promoting a new product if they are not sure they will have the inventory to meet that demand?
Evidence of my theory:
Zero Raw Materials in the last financial report, one can't make ActiPatch without Raw Materials
If companies like Sony, Ford and Panasonic can't get orders filled for Chips how can a small player like BIEL
SAI has had to delay their Powered By ActiPatch Launch for over a year now
Chemist 4U, who jumped in when ActiPatch was pulled from UK shelves, was out of stock for over 6 months, they just got new stock in the last few weeks
Amazon in India has been OOS for 6 plus months
The good news is that Powered By ActiPatch products have not been shunned by OEM Partners or consumers. A world wide pandemic disrupted the supply of Chips. Chip manufacturers continue to make progress in fixing the problem as they want to fill all of the orders that they receive just as BIEL does.
LOL, Glad to see that this was labeled, "I don't believe", "IMO"
<<<<<<< They haven't spent much and they don't intend to spend much >>>>>>>>>
KT Tape purchases from BIEL, that have been documented with Customs BOLs, shipped to KT's Utah warehouse:
12/21/2020 - 3,770 cartons, 18 pallets, 9,554 lbs , BOL#ZIMUHKG83124564
4/25/2021 - 4,332 cartons, 20 pallets, 11,384 lbs, BOL#00LU2661696645
6/28/2021 - 2,848 cartons, 14 pallets, 7,790 lbs, BOL#00LU2665591762
This is somewhere between $500k - $800k and worth of product depending on exactly what KT pays for each Wave and how many units there are per case.
Q4 2020 and Q2 2021, which is when these 3 shipments occurred, had a combined revenue of $931k.
In addition to product cost KT, like any company, has many other associated costs with its products; warehousing, shipping, advertising, expansion to ROW, ect..
So, to say that KT has "not spent much" is nonsense. KT has a large investment in the Wave.
The Fact that KT has expanded the Wave outside of their initial North American OEM contract; UK, Spain, Australia, Estonia, Latvia, Lithuania, is a strong indicator of KT's confidence in the Wave.
LOL, I must be mistaken then
<<<<<<<<<< I never claimed BIEL had control over Amazon >>>>>>>>>>>>>>>
209191
"Why Homeopathic remediy is the wrong category
Biel should ask Amazon to change this."
Once again BIEL has no control over what Amazon Category the KT Wave sells under.
BIEL makes the Wave for KT Tape under an OEM Contract, that's it.
All Distribution, Marketing, Advertising and Pricing decisions are made by KT since the Wave is their product.
Trying to blame BIEL because the KT Wave is sold in a Homeopathic Category is ridiculous.
Anyone who is annoyed by this issue should complain to KT Tape.
It was actually "in excess of $200,000.00" from 3 customers
"BioElectronics Corporation is pleased to announce that it has signed two additional international distribution partners and received a new order from its longtime distribution partner in Bangladesh, Multiple Health Pharma, Ltd., who has resumed operations following shutdowns due to Covid. These two new international orders and the renewal order total in excess of $200,000.00."
"The first new order comes from Stada MENA DWC-LLC. It will be distributing ActiPatch in Bahrain and the Kingdom of Saudi Arabia. Erin Sanders, International Sales Manager for BioElectronics, said, “After lengthy negotiations and delays due to Covid, I am pleased to close the contract and bring on this well qualified and capable distribution partner.” "
"Ms. Sanders has also finalized a contract with Modern Development Medical Company., which will be distributing both RecoveryRx and ActiPatch in Kuwait, Qatar, and Oman. In the United Arab Emirates, they will be focusing on the RecoveryRx brand. "
This was stated on 2/28, 31 days before the end of Q1, and was not stated as a total to that date, just a snap shot of 3 International orders.
As far as Amazon goes, BIEL has already recognized the revenue from the devices being sold on Amazon. It matters because every device sold brings KT closer to their reorder point.
As far as, "has been a lot higher than #78", we got a daily, sometimes hourly, announcement when the Wave was out of the 'Top 100' and silence from the same source when sales increases moved KT back to the 'Top 100'. So unless one complained about the 'out of the top 100' announcements .......
BIEL has no control over the Amazon Category that KT Wave occupies
BIEL is the Manufacturer. KT Tape is the Distributor/Retailer.
The category is chosen by the Seller listing the product on Amazon.
For those not aware the Amazon Sales ranking is based on the last hour of Sales, updating shortly after the top of the hour.
At 10:12 this morning it was 78 for the Wave.
Hummm, KT Wave moving from the #136 spot on Amazon last week to #78 this week is not significant???
A move of 58 places in one week sounds amazing .
Disinformation about BIEL, "going nowhere fast".
Ruh Roh, Amazon Places Wave at #78 in Sales out of over 2,000 products in Class
Looks like all the claims of declining Sales were Bullshit.
Go BIEL !!!
Go KT Tape !!!
https://www.amazon.com/KT-Tape-Recovery-Electromagnetic-Relief/dp/B08WTN6V2Y/ref=asc_df_B08WTN6V2Y?tag=bingshoppinga-20&linkCode=df0&hvadid=80264458823820&hvnetw=o&hvqmt=e&hvbmt=be&hvdev=c&hvlocint=&hvlocphy=&hvtargid=pla-4583863991608800&psc=1
Thanks toohot, ActiPatch in use at Korea's Largest Plastic Surgery Hospital
http://wonjinbeauty.com/en/about/safe_equipment_system.php (scroll down page)
"Actipatch Pain Care - It is a low frequency pain relief product without a tingling discomfort and help to recover comfortably."
Wonjin Plastic Surgery has 40 doctors servicing patients.
http://wonjinbeauty.com/en/about/professional_medical_surgeons.php
EYE SURGERY
WONJIN’S Eyelid Surgery System
Non Incision/ Incision
Ptosis Correction
Upper Blepharoplasty (For Middle Aged)
Brow Lift (For Middle Aged)
Canthoplasty
Under Eye Bag Correction
Lower Blepharoplasty (For Middle Aged)
Love Band
Revision Surgery
RHINOPLASTY
WONJIN’S Rhinoplasty
Nasal Bridge Surgeries
Nasal Tip Surgeries
Otorhinolaryngology(Ent)
Revision Rhinoplasty
BREAST SURGERY
Breast Surgery System
Breast Augmentation
Breast Reduction & Lifting Surgery
Nipple Surgery
Male Breast Reduction(Gynecomastia)
BODY CONTOUR
WONJIN’S Body Contour System
Liposuction
Tummy Tuck
Buttocks Surgery
Calf Reduction
Non-Invasive Body Contouring
Gynoplasty
ANTI-AGING (+LIPS) & HAIR LOSS
WONJIN’S Anti-Aging System
Thread Lifting
Laser Lifting
Incisional Lifting
W-Ell Procedures
Fat Grafting
Filler
Lip Corner Lifting
Hair Loss Treatment
FACIAL CONTOUR
WONJIN’S Facial Contour System
Facial Contour Surgery
Two Jaw Surgery
DERMATOLOGY CLINIC
WONJIN’S Dermatology Clinic
Experienced Specialist
Skin Treatment
Petit Treatment
Anti-Aging
Body Clinic
Laser Hair Removal
About the same time frame as the predictions of "BK any day"
<<<<<<<<< my god how long have people been saying “very soon “ >>>>>>>>>>>>
There has been No BIEL BK.
There has been progress by BIEL towards solvency including a Green Q3 2021.
BioElectronics Corporation Reports Q3 Earnings
Nov. 16, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (BIEL) (https://www.bielcorp.com/ OTC: BIEL) announces a 463% increase in sales revenue resulting in a profitable 3rd quarter.
Keeping in line with BIEL’s impressive year-over-year growth, the nine months ended September 30, 2021 sales were 463% higher than the same period during 2020. Additionally, Deferred revenue amounted to $256,398 at the quarter’s close; this revenue will be recorded as sales in the applicable quarter when the products are shipped.
Forgot to mention that there are over 2,000 products currently in the Homeopathic category
Some that have been selling on Amazon for over a decade.
KT's Wave was introduced last year.
#94 out of 2,231 .
https://www.amazon.com/s?k=Pain+Relief+Homeopathic+Remedies&i=hpc&rh=n%3A3763571&page=30&qid=1651678800&ref=sr_pg_30
Hooray!!!!!!! BIEL got Another Upgrade
From the impending Doom proclamation of 'any day now' to 'last year of operations'.
I can see the next backtrack coming, 'one million per Quarter is not near enough needs to be 5 million per Quarter'.
LMFAO, KT Wave Moves Up to Amazon Top 100 List
And that is now meaningless, needs to be on top 10.
You couldn't make this Bullshit up in your wildest dreams!
That is one Opinion
If one compares the negative Opinions to those such as myself, who use it every week to enhance mobility and life in general, it would be a one hundred+ to one ratio in favor of ActiPatch.
I shared Facts related to BIEL, unlike the Personal Opinions that I responded to.
Trash Talk
BIEL has achieved 5 FDA Indications, indications that most medical device companies spend $30 million a piece for.
BIEL received all of those FDA Clearances for an Accumulated Deficit of $38.3 million, investor money well spent to gain regulatory approvals.
Full Body OTC Musculoskeletal Pain was the important one granted on 2/3/2020. The FDA reviewed 3 Clinical Studies and said that ActiPatch was a Safe and Effective pain reliever for use on every Muscle, Joint and Bone in the body.
Since the Full Body Clearance BIEL has Partnered with 3 large, established companies to Market their own versions of ActiPatch products.
No mystery, Lenders want collateral
When IBEX started making large loans to BIEL in 2009 a Security Agreement was established granting priority of BIEL's assets to IBEX in the event of a default.
In 2018 when BIEL asked EXIM for a revised repayment schedule on their loans one of the EXIM conditions was that they received priority to BIEL's assets. IBEX got moved from first lender paid to second in line.
2021 EOY Financials, page 16
"According to the original Security Agreement dated August 1, 2009, the Company grants IBEX a security interest in, all of the right, title, and interest of the Company, in and to all of the Company’s personal property and intellectual property, and all proceeds or replacements as collateral for the convertible promissory note agreements. The Security Agreement has been subordinated to the EX-IM Bank."
Here we go again with the "All they had to do" Bullshit
Some are evidently not aware that starting a new business is not an easy task.
90% of new startups fail.
75% of venture-backed startups fail.
Under 50% of businesses make it to their fifth year.
33% of startups make it to the 10-year mark.
Only 40% of startups actually turn a profit.
82% of businesses that fail do so because of cash flow problems.
By surviving and making progress towards solvency for 20 years BIEL has beaten the odds.
Yep pinhigh, at least 8 years remain on BIEL's Patent
Companies can effectively extend their patent life by adding improvements to their product and filing for a new patent.
Someone brought up BIEL's Patents in a PM and was concerned about expirations, I thought it may be good to post as others may also be interested
Patents are valid for 20 years from the date of the application and no shorter than 17 years from the date of approval.
PULSED ELECTROMAGNETIC FIELD DEVICE WITH ADHESIVE
APPLICATOR (valid until 10/2032)
Publication number: 20140249355
Filed: October 22, 2012
Publication date: September 4, 2014
Electromagnetic therapy device and methods (valid until 4/2030)
Patent number: 8412328
Filed: May 21, 2003
Date of Patent: April 2, 2013
This Patent has the following statement: "This application is a continuation-in-part and claims the benefit of priority from U.S. patent application Ser. No. 10/384,101, filed Mar. 6, 2003 now U.S. Pat. No. 7,551,957 and entitled “Electromagnetic Therapy Device and Methods,” which is incorporated herein by reference in its entirety." ( looks like BIEL may have done some duplication filing and delayed approval that extended the original patent life 4 years)
Insole Electromagnetic Therapy Device (valid until 3/2032)
Publication number: 20120245403
Filed: March 23, 2012
Publication date: September 27, 2012
Electromagnetic therapy device and methods (valid until 6/2026)
Patent number: 7551957
Filed: March 6, 2003
Date of Patent: June 23, 2009
Pulsed electromagnetic field device with peel-off style mounting strip (valid until 10/2031)
Patent number: D706432
Filed: October 5, 2011
Date of Patent: June 3, 2014
LOL, Yes, the MMs are all model citizens following every regulation that governs them.
One of the most blatant Naked Shorting Scams in history happened just a year ago. Naked Shorters increased the Game Stop Authorized share count by 40 % more shares than were in existence, a $359 million scam.
The GameStop Mess Exposes the Naked Short Selling Scam
It’s a scam central to the stock trading system, enabled by the Securities and Exchange Commission (SEC), the market regulator, and the Depository Trust and Clearing Corp. (DTCC), the stock clearinghouse, to benefit the big players. The SEC has long been run by revolving-door officials who move between it and Wall Street trading houses and law firms. DTCC is owned by the prime brokers, such as Goldman Sachs, JPMorgan, and Citi, and run in their interests.
It’s a scam central to the stock trading system, enabled by the Securities and Exchange Commission, the market regulator.
At the House hearing, Rep. Nydia Velazquez (D-NY) asked about the dangers of short selling. “GME [GameStop] sold short 140 percent. Why isn’t that manipulation?” She meant that short sellers sold 40 percent more shares in GameStop than existed. They were phantom shares that didn’t exist but that were posted in buyers’ accounts as “entitlements.” The buyers have no idea they don’t have real shares. They can sell and even loan those digital entitlements.
In other words, large numbers of “locates” or “borrows” were fake, making the shorts “naked.” Why does it matter? Because naked short selling causes the number of shares in the market to increase, which normally makes their value drop; more shares equals less value. And it can massively disrupt the market, as GameStop showed.
https://prospect.org/power/gamestop-mess-exposes-the-naked-short-selling-scam/
*********************************************************************************************
FINRA IMPOSES $2M FINE ON CANTOR FITZGERALD OVER VIOLATIONS OF SHORT-SELLING REGULATION
MARCH 5, 2019 5:38 PM UTC, MARIA NIKOLOVA
Cantor did not timely close-out at least 4,879 fails-to-deliver, and routed or executed thousands of short orders without first borrowing the security or issuing notice of the need for a pre-borrow.
https://financefeeds.com/finra-imposes-2m-fine-cantor-fitzgerald-violations-short-selling-regulation/
***************************************************************************************
FINRA Fines Interactive Brokers $5.5 Million for Regulation SHO Violations and Supervisory Failures
https://www.finra.org/media-center/news-releases/2018/finra-fines-interactive-brokers-5-point-5-million-regulation-sho
*******************************************************************************************
Citadel securities violations and fines
During 15 years, Citadel did not pay more than $32 million in fines for 59 market violations. A number of instances were documented as 'wilful' naked shorting by Citadel Securities. They have been fined 59 times for infractions of FINRA, REGSHO & SEC rules.
https://news.investorturf.com/citadel-securties-violations-and-fines
*******************************************************************************************
MASSIVE TRADING FIRM KNIGHT CAPITAL CHARGED WITH ABUSING “NAKED SHORTS”
Finra charged KCG on October 31 with thousands of violations of the SEC rule banning abusive “naked” short selling.
https://theintercept.com/2016/12/15/whistleblower-vindicated-massive-trading-firm-knight-capital-charged-with-abusing-naked-shorts/
******************************************************************************************
Wedbush Securities Sued for Naked Short Sale Scheme
Wedbush Securities, based in Los Angeles, California, was sued in California state court for a market manipulation scheme. The lawsuit alleges that Wedbush improperly executed naked short sales of Life Partners Holdings Inc.’s stock, engaged in a “massive, illegal stock market manipulation scheme” that caused Life Partners Holdings Inc.’s stock price to drop, and that Wedbush and other unnamed defendants have been executing phantom securities transactions since Oct. 1, 2009, in an effort to profit from additional fees, commissions, and interest.
https://dkrpa.com/blog/naked-short-sale/
******************************************************************************************
DOJ probe into shadowy underworld of short selling ‘long overdue’
Jaclyn JaegerBy Jaclyn JaegerTue, Jan 11, 2022 10:17 AM
“I believe [illegal short selling] is the largest commercial fraud in U.S. history. It makes the Bernie Madoff scheme look like a gnat on an elephant’s behind.”
Wes Christian, Partner, Christian Smith & Jewell
https://www.complianceweek.com/risk-management/doj-probe-into-shadowy-underworld-of-short-selling-long-overdue/31237.article
That comment was in relation to the 'Sky is Falling' posts trying to create panic so that they can Buy at a cheaper price.
When we see shares for sale there is no differentiation between the shares that are actually 'Legitimate Shares' and those that our MMs have created out of Thin Air to Maintain Liquidity or Manipulate the SP.
It is important to understand the OTC Market Maker trading system. The MMs are Wholesalers, those Buying & Selling OTC company shares are the Retail Customers.
So when you purchase shares of BIEL, either at the Ask or Bid SP, you are buying from the MM's Inventory of BIEL shares not from another Retail shareholder. The same principle applies when you Sell shares, everything goes through the MMs
The MMs can place whatever quantities they desire in their Bid/Ask Sizes. The 'Size' does not have to reflect their actual Inventory of shares because the MMs mandate is to Maintain Liquidity in the companies that they cover. If they run out of legitimate shares to sell they can sell Naked Short shares or buy shares in the Market.
If you are a MM would you want spend money buying Legitimate shares or Fill Buy Orders with Naked Short shares that cost you nothing and worry about Covering the Short later in the day, tomorrow, or next week?
The MM Naked Short/Cover Later business plan goes out the window when significant events occur for a company that trigger heavy volume and upward SP pressure.
Good Grief, more 'Sky is Falling' BS
Sell, Sell, Sell so that we can Buy, Buy, Buy
More Blah, Blah, Blah, you have no idea what the Q1 2022 Revenue will be
The imaginary forecasts from Sales-Track are Made Up Balone.
The only guidance BIEL has provided was from the 2/28/2022 Update that states 3 international customers had purchases totaling in excess of $200k. These were not the only purchases in Q1 just 2 new customers and 1 repeat order in the international markets. There were still 32 days left in the Quarter when this Update was published.
https://www.bielcorp.com/bioelectronics-corporation-chairman-richard-staelin-ph-d-updates-company-achievements/
Now that is a surprise......
An anonymous poster said ActiPatch did not work.
I will take the opinion of the FDA and their panel medical experts over an anonymous poster any day of the week.
FDA 510k #192234
Clinical Data:
The clinical data in this 510(k) includes results from three IRB approved,
randomized, controlled studies. Additionally, usability testing was
conducted to support the OTC use of the device.
• A randomized, controlled trial on chronic cervical osteoarthritis
(neck pain): This was a randomized, active-treatment controlled
study to evaluate the safety and effectiveness of the ActiPatch
medical device to reduce the pain level of patients diagnosed with
cervical osteoarthritis. The active-treatment control was an NSAID
of the Cox-2inhibitor family. There were 200 intent-to-treat
patients, out of which 197 completed the four-week study. There
were 142 women (71%) and 58 (29%) men in the study, with an
average age of 45 years. The primary endpoint for efficacy was
reduction in pain (VAS score) while at rest and being active, over
four weeks, when compared to the beginning of the study. The
results indicate that ActiPatch significantly reduced pain
(measured by VAS pain) associated with COA in the device
treatment group, and that the treatment differences between
device-treatment and NSAID-treatment groups was significant
(p<0.05).
• A randomized controlled trial on osteoarthritis of the knee: The
osteoarthritis of the knee study was a double-blinded, randomized,
placebo-controlled study to evaluate the safety and effectiveness of
the ActiPatch medical device to reduce the pain level of patients
diagnosed with knee osteoarthritis. The placebo treatment was a
device that was identical to ActiPatch but did not produce an
electromagnetic field when turned on. There were 66 intent-to-treat
patients, out of which 60 patients completed the four-week study.
There were 43 women (71.6%) and 17 (16.4%) men in the study,
with the following average demographics at baseline: 68 years of
age, BMI of 27.4 and disease duration of 12.1 years. The primary
effectiveness endpoints were improvements in pain level over the
four weeks as measured by the before and after VAS score and
WOMAC scores, and the primary safety endpoint was all
treatment-related adverse events during the study. The results
indicate that ActiPatch significantly reduced pain (measured by
VAS pain) associated with KOA in the device treatment group,
and that the treatment differences between active and placebo
treatment groups was significant (p<0.05).
• A randomized controlled trial on plantar fasciitis (heel pain): This
was a randomized, double-blinded, placebo-controlled study to
evaluate the safety and effectiveness of the ActiPatch medical
device to reduce the pain level of patients diagnosed with plantar
fasciitis. The placebo treatment was a device that was identical to
ActiPatch but did not produce an electromagnetic field when
turned on. A total of 70 patients were recruited into the study, and
all 70 completed the study. There were 52 women (74.4%) and 18
(25.6%) men in the study, with the following average
demographics at baseline: 51.5 years of age, BMI of 31.8 and
disease duration of 1.1 years. The primary effectiveness endpoint
was the daily morning (AM) VAS score, and the primary safety
endpoint was all treatment-related adverse events during the 7-day
study. The results indicate that ActiPatch significantly reduced
pain (measured by VAS pain) associated with PF in the device
treatment group, and that the treatment differences between active
and placebo treatment groups was significant (p<0.05).
• Usability testing was conducted in 46 men and women over the
age of 18 with a wide range of education levels who used the
RecoveryRx on the knee, lower back, or shoulder. The testing
showed that lay users understand the indications for use and when
not to use the device. In addition, the study showed that users
understand how to turn the device on, place it correctly on the right
part of the body, and how long to use the device.
https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192234.pdf
Time for a new calendar
KW took over as CEO in October 2019 which was 2 and 1/2 years ago.
In that time BIEL has:
Brought back Dr. Staelin to the BOD as COB
Added Keith Nalepka to the BOD
Moved to an OEM Business Plan for North America
Brought KT Tape, Scott/DonJoy, SAI Brands in as OEM Partners
Secured FDA Full Body Musculoskeletal OTC Clearance for ActiPatch
Received the EU CE Mark for both ActiPatch and RecoveryRx
Reduced BIEL's Interest payments by $2.5 million
Weathered a 100 year Pandemic
Achieved the first profitable Quarter in BIEL's 20 year history
Looks Like it's time for a History Lesson
BIEL has had a $29.99 RRP on the 720 hour ActiPatch for years.
Anyone who has been following BIEL for more than 3 years knows that they would offer wholesale pricing of $15 to those on their customer list once a year. BIEL still made a significant profit on those $15 sales, both direct to customers and to distributors, because the ActiPatch had a volume production cost of $2 per unit.
The $34.99 KT Wave has the same production costs as ActiPatch except for a less expensive 250 hour battery. KT's high RRP, for a 250 hour device when compared to the 720 hour Actipatch, gives them plenty of room to discount the price for promotions.
The KT Subscription price for the Wave is $27.99 per device and they still make a handsome profit.
Amazon currently has the KT Wave, an 'Amazon's Choice' Product, on sale for $23.99 and KT still makes a nice profit.
No "Dump", No "they are gone", just a common retail sales strategy.